Ballicules.com

Ramelteon

ROZEREM

Pronunciation: ram-EL-tee-on (roe-ZAIR-em)

Ramelteon ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Ramelteon ballicule
Ramelteon ROZEREM mascot mnemonic cartoon
Visual mnemonic: Ramelteon mascot
“Ram melty on Rose”

What it isMT1 and MT2 melatonin-receptor agonist; sleep-onset insomnia.

Why this oneIt is unscheduled and has no meaningful abuse or withdrawal liability, unlike benzodiazepine-site hypnotics.

What limits itEffect on sleep onset is modest. Strong CYP1A2 inhibition, especially fluvoxamine, can raise exposure markedly.

Ramelteon molecular structure (skeletal formula)
Molecular structure: Ramelteon

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Insomnia (sleep-onset)Adults8 mg QHS8 mg QHS8 mg/day

Renal No adjustment needed

Hepatic Caution in moderate impairment; not recommended in severe

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy No drug-associated risk identified in postmarketing data; teratogenic in rats at high multiples

Lactation Undefined

Cost

Ramelteon (ROZEREM)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/moCostPlus
8 mgtab30 qd$19.79offered

Generic entry2013

NO BOXED WARNINGS

Principal riskModest effect; contraindicated with fluvoxamine

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability3 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilitySomnolence and dizziness; overdose is generally less dangerous than sedative-hypnotics.

Open Ramelteon in the interactive console ↗

Memory aids: interaction avatars

Ramelteon CYP1A2 substrate avatar mnemonic
CYP1A2 substrate

Open Ramelteon in the interactive console ↗